Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOP vs Sequential High-Dose Chemotherapy With ASCT in Aggressive NHL (MISTRAL)
NCT00003215Phase 3Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Apr 1997
- Primary completion
- Mar 2004
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Cytokines & Interferons
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide, methotrexate, etoposide, mitoxantrone, melphalan and 1 more in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoints: Objective Response Rate, Overall Survival and 1 more. Started Apr 1997; status: completed.
02
Drugs
cyclophosphamidemethotrexateetoposidemitoxantronemelphalan
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00003215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003215.